Please login to the form below

Not currently logged in
Email:
Password:

J&J Ortho-McNeil division recalls Topamax

Johnson & Johnson's (J&J) Ortho-McNeil Neurologics Division has recalled two batches of its anti-seizure drug Topamax (topiramate) due to reports of an odour

Johnson & Johnson's (J&J) Ortho-McNeil Neurologics Division has recalled two batches, amounting to around 57,000 bottles, of its anti-seizure drug Topamax (topiramate) due to reports of an odour thought to be caused by trace amounts of TBA (2,4,6 tribromoanisole). TBA is a byproduct of a chemical preservative sometimes applied to wood often used in the construction of pallets on which products are transported and stored. 

The company said that although all bottles in the affected batches have been recalled, it believes fewer than 6,000 bottles remain in the marketplace. J&J has said that it does not anticipate a product shortage as a result of the recall.

J&J has initiated the recall voluntarily, in cooperation with the US Food and Drug Administration (FDA). The company will be carrying out investigations with its suppliers to verify that pallets treated with chemically-treated wood are not being used for the shipment of products.

Earlier this week, J&J appointed Denice Torres to lead its McNeil Consumer Healthcare division, which has recently has faced dozens of high-profile product recalls including Children's Tylenol, Motrin, Zyrtec and Benadryl.

14th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

Partnering with top global pharmaceutical companies, we push the boundaries to create meaningful, impactful and lasting learning opportunities. We leverage...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics